title: Pacing Therapies in Congestive Heart Failure II study.
abstract: Ventricular resynchronization therapy (VRT) by left or biventricular stimulation is gaining increasing acceptance as a new therapy in addition to drugs in patients with advanced heart failure and intraventricular conduction disturbances. Several studies have demonstrated acute hemodynamic benefit of VRT in these patients, although there are only limited long-term data in small patient cohorts. Many open questions remain: whether to pace both ventricles or the left ventricle alone, the optimal left ventricular pacing site, the criteria used to identify the optimal candidate for VRT (e.g., QRS width), and the importance of an integrated defibrillator function in a VRT device. The Pacing Therapy in Congestive Heart Failure (PATH-CHF) II study is a prospective, randomized, cross-over study currently investigating the potential benefit of VRT in a population with advanced heart failure, with or without an accepted indication for an implantable defibrillator. It focuses on the effects of optimized univentricular pacing in these patients, and both acute hemodynamic and chronic functional effects are assessed. Acute hemodynamic testing mainly investigates the impact of different left ventricular pacing sites, alone or combined with right ventricular sites, on hemodynamic performance. Primary endpoint of the study is an improvement in functional capacity as assessed by cardiopulmonary exercise testing and 6-minute walk distance; secondary endpoints include improvement in quality of life (assessed by Minnesota quality of life score, New York Heart Association (NYHA) functional class, and hospitalization frequency), and improvements in prognostic and hemodynamic parameters. The trial aims to enroll 64 patients with full datum sets (separately in 2 groups with a QRS of < or = 150 or > 150 msec, respectively) in 9 European centers. The enrollment began September 1998, and is expected to conclude in summer 2000 to reach the number of necessary datum sets.
authors.affiliation: University Hospital RWTH, Aachen, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Stellbrink
authors.forename: A
authors.initials: A
authors.lastname: Auricchio
authors.forename: C
authors.initials: C
authors.lastname: Butter
authors.forename: S
authors.initials: S
authors.lastname: Sack
authors.forename: J
authors.initials: J
authors.lastname: Vogt
authors.forename: D
authors.initials: D
authors.lastname: Böcker
authors.forename: M
authors.initials: M
authors.lastname: Block
authors.forename: H
authors.initials: H
authors.lastname: Kirkels
authors.forename: A
authors.initials: A
authors.lastname: Ramdat-Misier
mesh_terms: D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000628:therapy*; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D018592:Cross-Over Studies; D006333:Heart Failure / Q000150:complications*; D006439:Hemodynamics; D006801:Humans; D018579:Patient Selection; D011446:Prospective Studies; D012107:Research Design